Envista (NYSE:NVST - Get Free Report) is expected to be posting its Q3 2025 results after the market closes on Thursday, October 30th. Analysts expect Envista to post earnings of $0.27 per share and revenue of $639.4920 million for the quarter. Envista has set its FY 2025 guidance at 1.050-1.15 EPS.Individuals are encouraged to explore the company's upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 30, 2025 at 5:00 PM ET.
Envista (NYSE:NVST - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of $0.24 by $0.02. The business had revenue of $682.10 million during the quarter, compared to analyst estimates of $638.21 million. Envista had a return on equity of 4.84% and a net margin of 2.11%.The company's quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.11 EPS. On average, analysts expect Envista to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Envista Stock Down 1.1%
NVST stock opened at $19.86 on Thursday. The company has a quick ratio of 2.08, a current ratio of 2.44 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $3.30 billion, a PE ratio of 62.05, a PEG ratio of 1.08 and a beta of 1.01. Envista has a twelve month low of $14.22 and a twelve month high of $23.00. The stock has a 50-day simple moving average of $20.61 and a two-hundred day simple moving average of $19.11.
Institutional Trading of Envista
Hedge funds and other institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Envista by 73.1% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company's stock valued at $44,000 after purchasing an additional 949 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in Envista by 378.0% in the second quarter. EverSource Wealth Advisors LLC now owns 2,414 shares of the company's stock valued at $47,000 after purchasing an additional 1,909 shares during the last quarter. Captrust Financial Advisors lifted its position in Envista by 38.4% in the second quarter. Captrust Financial Advisors now owns 15,465 shares of the company's stock valued at $302,000 after purchasing an additional 4,290 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in Envista in the second quarter valued at approximately $318,000. Finally, Prudential Financial Inc. lifted its position in Envista by 22.1% in the second quarter. Prudential Financial Inc. now owns 18,785 shares of the company's stock valued at $367,000 after purchasing an additional 3,395 shares during the last quarter.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on the company. Stifel Nicolaus lifted their target price on Envista from $24.00 to $25.00 and gave the company a "buy" rating in a report on Friday, August 1st. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Envista in a report on Wednesday, October 8th. Piper Sandler lifted their target price on Envista from $17.00 to $19.00 and gave the company a "neutral" rating in a report on Friday, August 1st. UBS Group lifted their target price on Envista from $18.00 to $22.00 and gave the company a "neutral" rating in a report on Tuesday, July 29th. Finally, Zacks Research lowered Envista from a "strong-buy" rating to a "hold" rating in a report on Monday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Envista currently has an average rating of "Hold" and an average target price of $21.08.
Read Our Latest Research Report on Envista
Envista Company Profile
(
Get Free Report)
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Envista, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Envista wasn't on the list.
While Envista currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.